Impact of prolonged duration of different types of renal replacement therapies on serum levels of endothelin-1 and pulmonary function tests
Impact of prolonged duration of different types of renal replacement therapies on serum levels of endothelin-1 and pulmonary function tests
Blog Article
Introduction: This study was carried out to investigate the impact of duration of different renal replacement therapies such as hemodialysis and continuous ambulatory peritoneal dialysis on potential overproduction of endothelin-1 (ET-1) and Joint Care pulmonary function tests in these patients.Materials and methods: The study included 26 patients (14 males, mean age 54.9±16.2 years) with end stage renal diseases (ESRD) receiving regular hemodialysis (HD) and 23 patients (10 males, mean age 55.8±15.
8 years) with ESRD treated with continuous ambulatory peritoneal dialysis (CAPD).The spirometry values were recorded before the onset of HD and prior to emptying the peritoneal cavity in CAPD patients and ET-1 was measured using the enzyme immunoassay (EIA) methodology.Two groups of patients (groups 1 and 2) were further divided into subgroups (group A and group B).Groups A (1-A and 2-A) included patients treated with any type of renal replacement therapy Western bit (RRT) (HD or CAPD) less than 5 years, and groups B (1-B and 2-B) included patients treated with any type of RRT (HD or CAPD) longer than 5 years.Results: Patients treated with HD or CAPD for more than five years were found to have significantly higher serum levels of ET-1 (HD = 41.
49±21.28 vs.185.13±73.67, p<0.
01; PD = 51.24±32.11 vs.139.53±42.
42, p<0.01, respectively).Values of most pulmonary function parameters differed significantly between groups treated longer or shorter than 5 years: FVC (HD = 108.4±13.34 vs.
80.82±11.26, p<0.01; CAPD = 97.20±18.
99 vs.73.25±10.73, p<0.01, respectively), FEV1 (HD = 108.
33±15.8 vs.76.73±4.9, p<0.
01; CAPD = 100.67±18.31 vs.66.75±6.
25, p<0.01, respectively).Conclusions: Prolonged duration of any type of renal replacement therapy is associated with higher serum levels of ET-1 and with lower pulmonary function tests in ESRD patients.